Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including ...
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 500
- Registration Number
- NCT06509126
- Locations
- 🇮🇹
Istituto Nazionale Tumori di Napoli - IRCCS - Fondazione G. Pascale, Napoli, Italy
Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC
- Conditions
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Rui-hua Xu, MD, PhD
- Target Recruit Count
- 360
- Registration Number
- NCT06501664
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 130
- Registration Number
- NCT06493760
- Locations
- 🇨🇳
Liu Tianshu, Shanghai, Shanghai, China
Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes
- Conditions
- Interventions
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT06490913
Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 150
- Registration Number
- NCT06490003
- Locations
- 🇯🇵
Yamanashi Universiy, Chuo, Yamanashi, Japan
The Sagittarius Trial
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-11-11
- Target Recruit Count
- 700
- Registration Number
- NCT06490536
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Rozzano, Milano, Italy
🇮🇹Istituto di Candiolo, Candiolo, Torino, Italy
🇮🇹Azienda Sanitaria Locale di Biella, Biella, Italy
Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 87
- Registration Number
- NCT06475326
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 130
- Registration Number
- NCT06469944
- Locations
- 🇺🇸
University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927), Tucson, Arizona, United States
🇧🇷Liga Norte Riograndense Contra o Câncer ( Site 6303), Natal, Rio Grande Do Norte, Brazil
🇩🇪Facharztzentrum Eppendorf-Facharztzentrum Eppendorf ( Site 6807), Hamburg, Germany
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 84
- Registration Number
- NCT06441565
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Pei-Rong Ding
- Target Recruit Count
- 66
- Registration Number
- NCT06417476
- Locations
- 🇨🇳
651 Dongfeng Road East, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.